Autologous or allogenic<unk> s harvested from bone marrow or peripherally
Treats various malignant and benign heme/onc diseases
Leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome
Severe aplastic anemia and bone marrow failure, inherited blood dyscrasias or immune deficiencies
Phases of recipient transplant process
Conditioning with radiation (usually total body) and/or chemotherapy
Goals: eliminate underlying malignancy, prevent rejection
Infusion
Neutropenic phase (weeks 2-4): no functioning immune system
Engraftment phase: highest risk of acute GVHD, lasts several weeks
Post-engraftment phase
Leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome
Severe aplastic anemia and bone marrow failure, inherited blood dyscrasias or immune deficiencies
Conditioning with radiation (usually total body) and/or chemotherapy
Goals: eliminate underlying malignancy, prevent rejection
Infusion
Neutropenic phase (weeks 2-4): no functioning immune system
Engraftment phase: highest risk of acute GVHD, lasts several weeks
Post-engraftment phase
Goals: eliminate underlying malignancy, prevent rejection
Stem cell transplant complications
Higher risk with allogenic transplant
Transplant complications
Stroke
Oncologic therapy related adverse events
Median time of presentation 28 days post-transplant
Lung transplant complications
Usually hemorrhagic due to thrombocytopenia